Palatin Technologies, a biopharmaceutical company, announced its common stock will transfer from the NYSE American to the Nasdaq Capital Market starting May 29, 2026, continuing under the symbol "PTN." The move aims to increase stock visibility, improve trading liquidity, and attract more institutional investors. Palatin focuses on developing treatments for rare obesity disorders linked to the MC4R pathway, with key drug candidates progressing toward IND submissions in late 2026 and early 2027. Existing shareholders do not need to take any action regarding the listing transfer.
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...
The global anthracite market, valued at $11.9 billion in 2025, is projected to grow to $16.8 billion by 2035 with a 3.5% CAGR. Growth is fueled by rising demand in steel production, water filtration, and advanced industrial uses due to anthracite's h...
